17:47 , Jun 28, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Conjugates Hafnium (Hf)-based metal-organic complexes could enhance the sensitivity of solid tumors to radiotherapy. The complexes consist of nanoscale frameworks of six or 12 Hf atoms coordinated to molecules of 2,5-di( p -benzoato)aniline (DBA),...
20:43 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Nanobiotix’s NBTXR3 meets in Phase II/III for STS

Nanobiotix S.A. (Euronext:NANO) said NBTXR3 (PEP503) met the primary and secondary endpoints in the Phase II/III act.in.sarc trial to treat locally advanced soft tissue sarcoma. The compound comprises crystalline nanoparticles of hafnium oxide activated in...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
00:11 , Dec 22, 2017 |  BC Week In Review  |  Financial News

JHL delisting from TPEx

JHL Biotech Inc. (TPEx-E:6540) said it will voluntarily delist from the Taipei Exchange in a move that its board believes will allow the company to advance and expand its biosimilars pipeline. The company said it...
01:40 , Dec 21, 2017 |  BC Extra  |  Financial News

JHL delisting from TPEx

JHL Biotech Inc. (TPEx-E:6540) said it will voluntarily delist from the Taipei Exchange in a move that its board believes will allow the company to advance and expand its biosimilars pipeline. The company said it...
21:48 , Apr 4, 2017 |  BC Week In Review  |  Clinical News

NBTXR3: Ph II/III Act.In.Sarc ongoing

An IDMC recommended continuation of the open-label, international Phase II/III Act.In.Sarc trial of a single intratumoral injection of NBTXR3 followed by radiotherapy and surgery based on safety and efficacy data from 104 patients. Act.In.Sarc is...
22:17 , Jan 12, 2017 |  BC Week In Review  |  Company News

Merrimack, Ipsen deal

Ipsen will acquire the commercial business of Merrimack, including U.S. rights to Onivyde irinotecan and Merrimack’s generic doxorubicin product. The companies expect the deal to close this quarter. Merrimack markets Onivyde to treat metastatic pancreatic...
00:30 , Jan 10, 2017 |  BC Extra  |  Company News

Ipsen acquiring Merrimack's marketed products

Ipsen Group (Euronext:IPN; Pink:IPSE) is acquiring the commercial business of Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) for $575 million up front and up to $450 million in milestones. The deal includes U.S. rights to Onivyde irinotecan, as...
22:20 , Jan 6, 2017 |  BioCentury  |  Finance

Tiers of disappointment

A bad year for biotech was closed with an even worse 4Q16 as volatility ahead of the U.S. elections and continued concerns around drug pricing held every market cap band in the red despite a...